Form 4 for GILD Gilead Sciences
Accepted 2023-03-13 00:00:00 ET · period of report 2023-03-10 · accession 0001127602-23-009984 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-03-13 | 2023-03-10 | GILD | Patterson Sandra | SVP, Controllership | M - OptEx | — | +2,921 | 25.7K | +13% | — |
| D | 2023-03-13 | 2023-03-10 | GILD | Patterson Sandra | SVP, Controllership | F - Tax | $79.50 | -801 | 26.2K | -3% | -$63.7K |
| DM | 2023-03-13 | 2023-03-10 | GILD | Patterson Sandra | SVP, Controllership | A - Grant | $0.00 | +16.5K | 22.6K | +275% | $0 |
| DM | 2023-03-13 | 2023-03-10 | GILD | Patterson Sandra | SVP, Controllership | M - OptEx | — | -2,921 | 17.7K | -14% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-10 | M | A | 1,320 | — | 27,013 | D | — | — | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. |
| 2 | Common | Common Stock | 2023-03-10 | F | D | 801 | $79.50 | 26,212 | D | — | — | |
| 3 | Common | Common Stock | 2023-03-10 | M | A | 1,601 | — | 25,693 | D | — | — | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. |
| 4 | Derivative | Non-qualified Stock Option (Right to Buy) | 2023-03-10 | A | A | 10,405 | $0.00 | 10,405 | D | $79.50 · — to 2033-03-10 | 10,405 Common Stock | (F4) The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
| 5 | Derivative | Restricted Stock Unit | 2023-03-10 | M | D | 1,320 | — | 16,428 | D | — · — to — | 1,320 Common Stock | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. (F3) The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
| 6 | Derivative | Restricted Stock Unit | 2023-03-10 | M | D | 1,601 | — | 17,748 | D | — · — to — | 1,601 Common Stock | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. (F2) The restricted stock units have a four year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. |
| 7 | Derivative | Restricted Stock Unit | 2023-03-10 | A | A | 6,130 | — | 22,558 | D | — · — to — | 6,130 Common Stock | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. (F3) The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. |